Diabetic Neuropathy - Pipeline Review, H1 2018

  • ID: 4542977
  • Drug Pipelines
  • 103 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Arena Pharmaceuticals Inc
  • Commence Bio Inc
  • Grunenthal GmbH
  • Medifron DBT Co Ltd
  • NovaLead Pharma Pvt Ltd
  • MORE
Diabetic Neuropathy - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H1 2018, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights:

This latest pipeline guide Diabetic Neuropathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 3, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Arena Pharmaceuticals Inc
  • Commence Bio Inc
  • Grunenthal GmbH
  • Medifron DBT Co Ltd
  • NovaLead Pharma Pvt Ltd
  • MORE
Introduction

Report Coverage

Diabetic Neuropathy - Overview

Diabetic Neuropathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Neuropathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Neuropathy - Companies Involved in Therapeutics Development

Achelios Therapeutics Inc

Angelini Group

Arena Pharmaceuticals Inc

Bristol-Myers Squibb Co

Commence Bio Inc

Grifols SA

Grunenthal GmbH

Immune Pharmaceuticals Inc

Kineta Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Neuralstem Inc

NovaLead Pharma Pvt Ltd

Novaremed Ltd

Omeros Corp

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Sphaera Pharma Pte Ltd

ViroMed Co Ltd

Diabetic Neuropathy - Drug Profiles

(amitriptyline + ketamine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diclofenac sodium + triclocarban) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AAD-2004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atexakin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNV-222 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNV-2197944 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyndacel-M - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

donaperminogene seltoplasmid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCP-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoprofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KU-32 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-652 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSC-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLP-198 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRD-135SE1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSI-189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olorinab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDA-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirenzepine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTA-901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block CACNA1H for CNS Disorders, Toxicology and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium nitrite SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trazodone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XK-568b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diabetic Neuropathy - Dormant Projects

Diabetic Neuropathy - Discontinued Products

Diabetic Neuropathy - Product Development Milestones

Featured News & Press Releases

Apr 12, 2018: AARP Calls ViroMed’s VM202 “Hope” for Peripheral Neuropathy

Mar 16, 2018: Reata to Present on its Diabetic Neuropathy Drug Candidate RTA-901 at the BIO Asia International Conference

Oct 30, 2017: VM BioPharma Announces Generic Name “donaperminogene seltoplasmid” for Investigational Novel Gene Therapy, VM

Sep 25, 2017: ViroMed, Gene Therapy Powerhouse on Global Stage

Aug 02, 2017: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy

Sep 08, 2016: ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy

Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition

Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial

Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy

Feb 07, 2008: EpiCept Announces Encouraging Results Of Phase II Trial For NP-1 Cream In Diabetic Peripheral Neuropathy

Dec 03, 2007: Patient Enrollment Gets Completed In Phase IIb Trial Of EpiCept NP-1 In Diabetic Peripheral Neuropathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Diabetic Neuropathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Diabetic Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2018

Diabetic Neuropathy - Pipeline by Angelini Group, H1 2018

Diabetic Neuropathy - Pipeline by Arena Pharmaceuticals Inc, H1 2018

Diabetic Neuropathy - Pipeline by Bristol-Myers Squibb Co, H1 2018

Diabetic Neuropathy - Pipeline by Commence Bio Inc, H1 2018

Diabetic Neuropathy - Pipeline by Grifols SA, H1 2018

Diabetic Neuropathy - Pipeline by Grunenthal GmbH, H1 2018

Diabetic Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H1 2018

Diabetic Neuropathy - Pipeline by Kineta Inc, H1 2018

Diabetic Neuropathy - Pipeline by Medifron DBT Co Ltd, H1 2018

Diabetic Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

Diabetic Neuropathy - Pipeline by Neuralstem Inc, H1 2018

Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt Ltd, H1 2018

Diabetic Neuropathy - Pipeline by Novaremed Ltd, H1 2018

Diabetic Neuropathy - Pipeline by Omeros Corp, H1 2018

Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H1 2018

Diabetic Neuropathy - Pipeline by Relief Therapeutics Holding AG, H1 2018

Diabetic Neuropathy - Pipeline by Sphaera Pharma Pte Ltd, H1 2018

Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H1 2018

Diabetic Neuropathy - Dormant Projects, H1 2018

Diabetic Neuropathy - Dormant Projects, H1 2018 (Contd..1), H1 2018

Diabetic Neuropathy - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Diabetic Neuropathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Achelios Therapeutics Inc
  • Angelini Group
  • Arena Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Commence Bio Inc
  • Grifols SA
  • Grunenthal GmbH
  • Immune Pharmaceuticals Inc
  • Kineta Inc
  • Medifron DBT Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Neuralstem Inc
  • NovaLead Pharma Pvt Ltd
  • Novaremed Ltd
  • Omeros Corp
  • Reata Pharmaceuticals Inc
  • Relief Therapeutics Holding AG
  • Sphaera Pharma Pte Ltd
  • ViroMed Co Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll